PreCare Trial & Recruitment B.V.

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Obesity4 trials
• Type 2 diabetes3 trials
• COPD2 trials
• Alzheimer disease1 trial
• Heart failure1 trial
• Type 1 diabetes1 trial

Phase

• Phase 37 trials
• Phase 21 trial

Status

• Completed5 trials
• Active, not recruiting2 trials
• Recruiting1 trial

Lead sponsor

• Boehringer Ingelheim2 trials
• Chiesi Farmaceutici S.p.A.2 trials
• Novo Nordisk A/S2 trials
• AstraZeneca1 trial
• Merck Sharp & Dohme LLC1 trial

Running trials

• Recruiting

  A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

  NCT07564414· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss

  NCT07503210· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

  NCT06677060· Phase 3· AstraZeneca· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure1 recruiting

Closed trials

• Completed

  A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of MK-1167 as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer’s Disease Dementia

  2024-515539-31-00· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

  NCT06066528· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

  NCT06066515· Phase 3· Boehringer Ingelheim· Source

• Completed

  The efficacy and safety of two doses of CHF6001 DPI as add-on to maintenance COPD triple therapy

  NCT04636814· Phase 3· Chiesi Farmaceutici S.p.A.· Source

• Completed

  The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD)

  NCT04636801· Phase 3· Chiesi Farmaceutici S.p.A.· Source